|This message contains images. If you don't see images, click here to view.|
Advertise in this news brief.
FSP 2015 Summer Anatomic Pathology Conference!
You don't want to miss the great topics and speakers scheduled for the FSP 2015 Summer Anatomic Pathology Conference. The event will take place July 25-26, 2015, at The Boca Raton Resort in Florida. More information on the program, speakers and registration will be available soon at www.flpath.org.
The FSP at work this legislative session
Here are a list of bills currently being presented during the Florida state legislative session with potential impact on our profession. We will continue to monitor their progress and report developments in the coming weeks. Please note that the links will continuously update. Stay tuned!
As medical laboratory test utilization grows, health insurers develop programs to manage rising costs
Health insurers are taking more aggressive actions to control the cost of clinical laboratory testing. For many years, clinical laboratories and pathology groups have been concerned about the strategies used by Medicare to control the utilization and costs of medical laboratory tests. Private health insurers usually follow the actions of Medicare, the nation’s largest health insurer. But today, managed care plans are developing their own lab-test-utilization strategies in addition to following those of Medicare.
UWF receives $100,000 for laboratory sciences scholarship
Pensacola News Journal
The University of West Florida recently celebrated a gift of $100,000 to UWF's Clinical Lab Sciences program by Dr. Ranga Rao Krothapalli, in memory of his wife, UWF Professor Emeritus Swarna Krothapalli. The Professor Emeritus Swarna Krothapalli Endowed Scholarship for Clinical Laboratory Sciences will honor the faculty member who had a lifelong dedication to students and impacted the lives of thousands in Clinical Lab Sciences and Medical Technology.
Whole genome sequencing may help identify disease risks
Would you want to know if you or your children had risk of hereditary cancer, a genetic risk for cardiovascular disease or carried the gene associated with developing Alzheimer's disease — even if they were risks that wouldn't be relevant for possibly decades or didn't have a cure? Using a small amount of blood or saliva, a technology called whole genome sequencing makes that possible — and more than half of parents said they'd not only be interested in the technology for themselves but for their children too, a new nationally-representative University of Michigan study shows.
Clinical, laboratory parameters predict early pancreatic adenocarcinoma mortality
Patients with pancreatic adenocarcinoma who had a high Khorana score or elevated blood urea nitrogen at baseline demonstrated a significantly greater risk for mortality within 6 months after surgical resection, according to study results.
Labs rarely report clinical trial data on time
According to United States law, studies of potential medicines and diagnostics are supposed to make their results publicly available within 12 months. But up to half of studies don't follow the rules — and no one has ever faced penalties.
Understanding the role of next generation sequencing in stratified cancer medicine
Oxford Gene Technology (OGT), The Molecular Genetics Company, has teamed up with clinical research experts in a new article available online, discussing the role of next generation sequencing (NGS) in cancer medicine. The article, titled "The role of NGS in stratified cancer medicine," presents a valuable resource to better understand the present and the future of NGS in stratified cancer medicine, detailing the most relevant aspects of this revolutionary technology.
ABI Research: Hospitals to benefit as IoT services increase lab test efficiency to 3.02 billion more tests by 2020
Hospital laboratories are the smallest share of laboratory locations yet diagnostic test equipment run more tests than any other medical testing facility provider. Connectivity to lab equipment and the services enabled by that connectivity will increase total global laboratory test throughput to over 3.02 billion more diagnostic tests over the next five years, according to ABI Research, adding that the medical testing laboratory market consists of hospitals, independent labs, physicians' offices and other labs.
U of M survey: 58 percent of parents interested in genome sequencing for their children
Many parents say they would want to know whether their children are genetically predisposed to certain diseases. A survey from the University of Michigan finds 58 percent of moms and dads would be interested in whole genome sequencing for their children. Mothers overall and those with young children who have health problems were most likely to desire such testing.
Novel anticoagulants target cancer patients with CVC
By Dr. Afsaneh Motamed-Khorasani
Anticoagulants have been traditionally used to treat venous thromboembolism, which is a major healthcare problem. Sometimes, there is a need in cancer patients to have a central venous catheter, which could in turn increase the chance of thrombosis. Therefore, the potential for the use of parenteral anticoagulants is being studied in ambulatory cancer patients undergoing chemotherapy, radiation or hormonal therapies that otherwise lack the prophylactic or therapeutic indication for the use of these category of drugs.
Miss an issue of Pathology Today? Click here to visit the Pathology Today archive page.
Nanotechnology shows promise for more accurate prostate cancer screening, prognosis
A Northwestern University-led study in the emerging field of nanocytology could one day help men make better decisions about whether or not to undergo aggressive prostate cancer treatments. Technology developed by Northwestern University researchers may help solve that quandary by allowing physicians to identify which nascent cancers are likely to escalate into potentially life-threatening malignancies and which ones will remain "indolent," or non-aggressive.
Does your clinical lab or pathology group have the effective leaders it needs during these challenging times?
Some would argue that leadership in medical laboratories today has something in common with the opening line of a famous 19th century novel. "It was the best of times, it was the worst of times," is the first sentence in "A Tale of Two Cities," Charles Dickens' famous novel. Many pathologists and clinical laboratory managers would agree that this sentence accurately describes today's marketplace for medical laboratory testing.
Disclaimer: The authors, editors, and the Florida Society of Pathologists (FSP) Executive Committee affiliated with "Florida Pathology Today" e-Newsletter cannot and do not warrant the completeness, accuracy, non-infringement, merchantability, timeliness or fitness for a particular purpose of the information or views contained within this publication, or available through the links provided within articles contained within this publication.
FSP has no control over and does not officially endorse the content of the information available on the links contained in the "Florida Pathology Today" or links imbedded in articles within the "Florida Pathology Today." These links are provided as a courtesy only. Linked sites are not a part of the "Florida Pathology Today." The owners of those linked sites, and not FSP, own the intellectual property rights to the material on the linked sites. FSP cannot certify the accuracy of material published on linked sites. Additionally, the contents of this e-Newsletter and the above referenced links, including any advice, suggestions, and/or recommendations have NOT been generated as part of any professional evaluation.
The authors, editors, webmasters, and the FSP Board of Directors affiliated with the "Florida Pathology Today" e-Newsletter shall not be liable to anyone for any loss or injury caused in whole or in part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting or delivering this e-Newsletter and any information included in this e-Newsletter.
Under no circumstances will the authors, editors, webmasters, and the FSP Board of Directors affiliated with the "Florida Pathology Today" be liable to you or anyone else for any decision made or any action taken by you or anyone else in reliance on such information or view, or for any incidental, consequential, special, or similar damages even if advised of the possibility of such damages.
The above warranties are the only warranties of any kind either expressed or implied, including warranties of merchantability or fitness for any particular purpose.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063